ArticleOman journal of ophthalmology
Color vision and contrast sensitivity changes in patient with primary angle closure and primary angle closure glaucoma.
Article in Oman journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of the study was to assess color vision (CV) and contrast sensitivity (CS) in patients with primary angle closure glaucoma (PACG) and primary angle closure (PAC) and to correlate these changes with age-matched controls. In addition, to asses this correlation with optical coherence tomography (OCT) retinal nerve fiber layer (RNFL). MATERIALS AND
methodsCV (using D-15 and Ishihara test) and CS (using Spaeth Richman Contrast Sensitivity Test [SPARCS] and Pelli Robson test) were analyzed in patients with PACG (Group 1) (33 eyes), PAC (Group 2) (27 eyes), and controls (Group 3) (60 eyes). OCT RNFL and Humphrey visual field testing was also done for cases and controls.
resultsOut of a total of 33 eyes in Group 1, 2 (6%) eyes had no defect, 20 (60.6%) had protan defects, 2 (6%) had deutran defects, and 9 (27.3%) eyes had tritan defects. Of the 27 eyes in Group 2, 1 (3.7%) eye had no CV defect, 19 (70.3%) eyes had protan defects, and 7 (25.9%) eyes had tritan defects. None of the eyes in Group 2 had a deutran defect. Forty-seven (78.3%) eyes from Group 3 had no CV defect, 10 eyes (16.6%) had a protan defect, and 3 (5%) of the eyes showed a tritan defect. All Group 1 and Group 2 eyes had a C-Index of >1.4. Twenty-eight eyes had a total SPARCS score <70, 18 eyes belonged to Group 1, and 10 eyes belonged to Group 2. There was no statistically significant difference in central and peripheral CS (in all the quadrants) between Groups 1 and 2.
conclusionQualitative and functional vision parameters are affected even in PAC patients before PACG sets in clinically. Hence, early and regular screening of these parameters is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.